HOL-101
Diagnosis of Growth Hormone Deficiency (GHD)
Key Facts
About Hollenbeck Pharmaceuticals
Hollenbeck Pharmaceuticals is a private, pre-revenue biotech advancing HOL-101, a synthetic GHRH analog with dual diagnostic and therapeutic applications for Growth Hormone Deficiency. The company has secured Orphan Drug and Rare Pediatric Disease designations from the FDA and has completed a Pre-IND meeting, receiving written guidance on its development plan. With a strategy to potentially bring the diagnostic to market first, Hollenbeck is actively seeking collaboration and investment partners to advance the program in a global GHD market estimated at over $5 billion.
View full company profileAbout Hollenbeck Pharmaceuticals
Hollenbeck Pharmaceuticals is a private, pre-revenue biotech advancing HOL-101, a synthetic GHRH analog with dual diagnostic and therapeutic applications for Growth Hormone Deficiency. The company has secured Orphan Drug and Rare Pediatric Disease designations from the FDA and has completed a Pre-IND meeting, receiving written guidance on its development plan. With a strategy to potentially bring the diagnostic to market first, Hollenbeck is actively seeking collaboration and investment partners to advance the program in a global GHD market estimated at over $5 billion.
View full company profile